IGC Pharma, Inc. (IGC)
NYSEAMERICAN: IGC · Real-Time Price · USD
0.314
-0.007 (-2.09%)
Apr 28, 2026, 4:00 PM EDT - Market closed
IGC Pharma Employees
IGC Pharma had 70 employees as of March 31, 2025. The number of employees increased by 3 or 4.48% compared to the previous year.
Employees
70
Change (1Y)
3
Growth (1Y)
4.48%
Revenue / Employee
$15,800
Profits / Employee
-$92,086
Market Cap
30.97M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| Celularity | 123 |
| Evaxion | 46 |
| Senti Biosciences | 34 |
| Palatin Technologies | 29 |
| Boundless Bio | 28 |
| Tevogen Bio Holdings | 18 |
| Outlook Therapeutics | 17 |
IGC News
- 9 hours ago - IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase - Accesswire
- 6 days ago - IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion - Accesswire
- 8 days ago - IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia - Accesswire
- 14 days ago - IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout - Accesswire
- 20 days ago - Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts - Accesswire
- 21 days ago - IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease - Accesswire
- 4 weeks ago - IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness - Accesswire
- 5 weeks ago - IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025 - Accesswire